Patents by Inventor William Isom

William Isom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12453724
    Abstract: The invention relates to a sustained release biodegradable ocular implant containing axitinib dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
    Type: Grant
    Filed: April 9, 2025
    Date of Patent: October 28, 2025
    Assignee: OCULAR THERAPEUTIX, INC.
    Inventors: Charles D. Blizzard, Erica Kahn, Peter Jarrett, Rabia Gurses-Ozden, Rami El-Hayek, Elizabeth Braun, Joseph Iacona, Chintan Patel, Mark Ransbottom, Olivia Sherman, William Isom
  • Publication number: 20250235438
    Abstract: The invention relates to a sustained release biodegradable ocular implant containing axitinib dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
    Type: Application
    Filed: April 9, 2025
    Publication date: July 24, 2025
    Inventors: Charles D. BLIZZARD, Erica KAHN, Peter JARRETT, Rabia GURSES-OZDEN, Rami EL-HAYEK, Elizabeth BRAUN, Joseph IACONA, Chintan PATEL, Mark RANSBOTTOM, Olivia SHERMAN, William ISOM
  • Patent number: 9539141
    Abstract: Compositions, devices, method of manufacture, and methods of delivery of a therapeutic substance across a surface of an eyeball via iontophoresis including a therapeutic media reservoir and a buffer system within an iontophoretic chamber. When energized, an electrode provides and electromotive force that transfers a dosage of the therapeutic substance from the iontophoretic chamber across the surface of the eyeball. The buffering system includes a buffer media and at least on buffer element, or agent that regulates pH during iontophoretic transfer of the therapeutic substance. The buffer media includes at least one of a foam, a gel (solid or liquid), a membrane, and a plurality of multi-particulates. The buffer media can be included within the iontophoretic chamber, together with the therapeutic media reservoir, in various arrangements including on or more layers and one or more concentric cylinders.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: January 10, 2017
    Assignee: Eyegate Pharmaceuticals, Inc.
    Inventors: Peyman Moslemy, Michael Manzo, William Schubert, William Isom, Pierre Roy
  • Publication number: 20160120696
    Abstract: Compositions, devices, method of manufacture, and methods of delivery of a therapeutic substance across a surface of an eyeball via iontophoresis including a therapeutic media reservoir and a buffer system within an iontophoretic chamber. When energized, an electrode provides and electromotive force that transfers a dosage of the therapeutic substance from the iontophoretic chamber across the surface of the eyeball. The buffering system includes a buffer media and at least on buffer elementt, or agent that regulates pH during iontophoretic transfer of the therapeutic substance. The buffer media includes at least one of a foam, a gel (solid or liquid), a membrane, and a plurality of multi-particulates. The buffer media can be included within the iontophoretic chamber, together with the therapeutic media reservoir, in various arrangements including on or more layers and one or more concentric cylinders.
    Type: Application
    Filed: November 2, 2015
    Publication date: May 5, 2016
    Inventors: Peyman Moslemy, Michael Manzo, William Schubert, William Isom, Pierre Roy
  • Patent number: 9180292
    Abstract: Compositions, devices, methods of manufacture, and methods of delivery of a therapeutic substance across a surface of an eyeball via iontophoresis including a therapeutic media reservoir and a buffer system within an iontophoretic chamber. When energized, an electrode provides an electromotive force that transfers a dosage of the therapeutic substance from the iontophoretic chamber across the surface of the eyeball. The buffering system includes a buffer media and at least one buffer element, or agent that regulates pH during iontophoretic transfer of the therapeutic substance. The buffer media includes at least one of a foam, a gel (solid or liquid), a membrane, and a plurality of multiparticulates. The buffer media can be included within the iontophoretic chamber, together with the therapeutic media reservoir, in various arrangements including one or more layers and one or more concentric cylinders.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: November 10, 2015
    Assignee: EYEGATE PHARMACEUTICALS, INC.
    Inventors: Peyman Moslemy, Michael Manzo, William Schubert, William Isom, Pierre Roy
  • Publication number: 20110301526
    Abstract: Compositions, devices, methods of manufacture, and methods of delivery of a therapeutic substance across a surface of an eyeball via iontophoresis including a therapeutic media reservoir and a buffer system within an iontophoretic chamber. When energized, an electrode provides an electromotive force that transfers a dosage of the therapeutic substance from the iontophoretic chamber across the surface of the eyeball. The buffering system includes a buffer media and at least one buffer element, or agent that regulates pH during iontophoretic transfer of the therapeutic substance. The buffer media includes at least one of a foam, a gel (solid or liquid), a membrane, and a plurality of multiparticulates. The buffer media can be included within the iontophoretic chamber, together with the therapeutic media reservoir, in various arrangements including one or more layers and one or more concentric cylinders.
    Type: Application
    Filed: December 28, 2009
    Publication date: December 8, 2011
    Applicant: EyeGate Pharmaceuticals, Inc.
    Inventors: Peyman Moslemy, Michael Manzo, William Schubert, William Isom, Pierre Roy